← FDA DRUG APPROVALS

FDA ANDA · ANDA065148

NYSTATIN

Sponsor: GENUS

APPLICATION
ANDA065148
TYPE
ANDA
ORIGINAL APPROVAL
2005-06-28
LATEST ACTION
2009-11-18
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

NYSTATINPrescription
NYSTATIN 100,000 UNITS/ML · SUSPENSION · ORAL

Approval history

2009-11-18Labeling · Supplement 1AP
2005-06-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →